NASDAQ: $NBIX
Recent findings presented at the Pediatric Endocrine Society 2026 Annual Meeting offer a promising outlook for the pediatric community living with classic congenital adrenal hyperplasia (CAH). Neurocrine Biosciences has released new two-year data from the Phase 3 CAHtalyst® Pediatric study, revealing that long-term treatment with CRENESSITY® (crinecerfont) provides durable hormone control and allows for significant, safer reductions in glucocorticoid (GC) dosing.
The Challenge of Traditional CAH Treatment
Congenital adrenal hyperplasia is a complex genetic condition that interferes with the production of vital adrenal hormones. Because patients cannot produce enough cortisol, they historically rely on supraphysiologic—or higher than necessary—doses of glucocorticoids to regulate their system. While these high doses are essential for survival, they are often linked to long-term health complications, including metabolic issues, weight gain, diabetes, and impaired growth patterns. For children, the challenge of balancing hormone levels while mitigating the side effects of steroids has long been a primary concern for both families and clinicians.
Key Findings: Sustained Results at Two Years
The study, which tracked 86 participants aged four to 17, demonstrated that CRENESSITY effectively targets the root of the problem by reducing adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP). The results show that these hormonal improvements are not only achievable but sustainable over a two-year period:
- Improved Metabolic Health: Among children who were overweight or obese at the start of the study, 60% experienced clinically meaningful improvements in their body mass index (BMI) by the two-year mark.
- Insulin Resistance: 61% of participants who presented with insulin resistance at baseline were no longer insulin resistant after two years of treatment.
- Hormonal Balance: The treatment enabled a reduction in daily glucocorticoid doses while successfully lowering levels of excess androgens, which are responsible for complications like acne and accelerated bone age.
Why This Matters for Pediatric Patients
Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, noted that these children are particularly vulnerable to the long-term impact of excess hormone exposure during their critical growth years. By enabling a more physiologic, lower-dose approach to steroid therapy, CRENESSITY acts as a tool to shift the treatment paradigm toward healthier, more sustainable outcomes as these patients transition into adulthood.
Dr. Mimi Kim, Principal Investigator for the CAHtalyst Pediatric study, emphasized that this approach addresses issues ranging from cardiovascular health to growth development. “These findings underscore the potential for CRENESSITY to redefine the treatment paradigm for patients with CAH,” Dr. Kim stated. “Providing sustained control of androgens and allowing for significant reductions in glucocorticoid dosing could ultimately lead to important improvements in key long-term patient outcomes.”
A Proven Safety Profile
Importantly, the data shows that CRENESSITY is generally well-tolerated, with an 80% retention rate over the two-year trial period and no new safety signals reported. This consistency provides significant reassurance for families navigating the challenges of managing a rare, life-long genetic condition.
As research continues, these two-year insights represent a vital step forward in the clinical management of classic CAH, offering families hope for a future where patients can achieve better hormonal control without the burden of excessive steroid exposure.
For more information on CRENESSITY and its use in pediatric patients, please consult your healthcare provider or visit the official Neurocrine Biosciences website. Always consult a doctor regarding medical decisions, and do not make changes to your glucocorticoid regimen without professional medical guidance.